Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17191286 | 0.65 | TIPARP (0.44) | BACE1MAPTMEN1KMT2A | |
| SCHEMBL13232537 | 0.60 | MAPT (0.67) | ADRB1BACE1MAPTMEN1KMT2A | |
| SCHEMBL31432954 | 0.60 | MAPT (0.67) | ADRB1BACE1MAPTMEN1KMT2A | |
| SCHEMBL7105773 | 0.60 | ADRB1 (0.70) | ADRB1DHFRMAPTMEN1KMT2A | |
| SCHEMBL10063748 | 0.60 | ADRB1 (0.70) | ADRB1DHFRMAPTMEN1KMT2A | |
| SCHEMBL9678667 | 0.60 | ADRB1 (0.56) | ADRB1DHFRACHEMAPTMEN1 | |
| SCHEMBL3414344 | 0.60 | ADRB1 (0.70) | ADRB1DHFRMAPTMEN1KMT2A | |
| SCHEMBL5854414 | 0.58 | ADRB1 (0.54) | ADRB1ACHEMAPTMEN1KMT2A | |
| SCHEMBL17191280 | 0.58 | ADRB1 (0.44) | ADRB1ACHEMAPTMEN1KMT2A | |
| SCHEMBL818462 | 0.57 | ADRB1 (0.58) | ADRB1DHFRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-103459384-A | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS INC | 2013-12-18 | — | — | CN | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | ADRB1 857/4885DHFR 3590/4885ACHE 3847/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | ADRB1 1082/4885DHFR 3730/4885ACHE 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.